Does ICER’s Psoriasis Drug Valuation Undercut Routine Step Therapy?

Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices. Paid subscription required to read more. (Source: Cathy Kelly, Pink Sheet, 12/9/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
Review of Influence: The Institute for Clinical and Economic Review 02/26/2019
ICER Releases Final Report for Type 2 Diabetes Add-on Therapies 12/10/2019
Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026 08/19/2019
The Global Use of Medicine in 2019 and Outlook to 2023 01/29/2019